Baxter International Inc. (NYSE:BAX) has agreed to sell its two commercially marketed vaccines and related production facilities to Pfizer Inc. for $635 million, subject to certain adjustments. The sale includes the company’s commercial vaccines business, made up of NeisVac-C, a vaccine which helps protect against meningitis caused by group C meningococcal meningitis (MenC), and FSME-IMMUN, which helps protect against tick-borne encephalitis (TBE), an infection of the brain transmitted b...